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Cardiovascular magnetic resonance native
T2 and T2
* quantitative values for
cardiomyopathies and heart
transplantations: a systematic review and
meta-analysis
G. J. H. Snel1*, M. van den Boomen1,2, L. M. Hernandez1, C. T. Nguyen2,3, D. E. Sosnovik2,3,4, B. K. Velthuis5,
R. H. J. A. Slart6,7, R. J. H. Borra1,6 and N. H. J. Prakken1
Abstract
Background: The clinical application of cardiovascular magnetic resonance (CMR) T2 and T2
* mapping is currently
limited as ranges for healthy and cardiac diseases are poorly defined. In this meta-analysis we aimed to determine
the weighted mean of T2 and T2
* mapping values in patients with myocardial infarction (MI), heart transplantation,
non-ischemic cardiomyopathies (NICM) and hypertension, and the standardized mean difference (SMD) of each
population with healthy controls. Additionally, the variation of mapping outcomes between studies was
investigated.
Methods: The PRISMA guidelines were followed after literature searches on PubMed and Embase. Studies reporting
CMR T2 or T2
* values measured in patients were included. The SMD was calculated using a random effects model
and a meta-regression analysis was performed for populations with sufficient published data.
Results: One hundred fifty-four studies, including 13,804 patient and 4392 control measurements, were included. T2
values were higher in patients with MI, heart transplantation, sarcoidosis, systemic lupus erythematosus, amyloidosis,
hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM) and myocarditis (SMD of 2.17, 1.05, 0.87, 1.39,
1.62, 1.95, 1.90 and 1.33, respectively, P < 0.01) compared with controls. T2 values in iron overload patients (SMD =
− 0.54, P = 0.30) and Anderson-Fabry disease patients (SMD = 0.52, P = 0.17) did both not differ from controls. T2
*
values were lower in patients with MI and iron overload (SMD of − 1.99 and − 2.39, respectively, P < 0.01) compared
with controls. T2
* values in HCM patients (SMD = − 0.61, P = 0.22), DCM patients (SMD = − 0.54, P = 0.06) and
hypertension patients (SMD = − 1.46, P = 0.10) did not differ from controls. Multiple CMR acquisition and patient
demographic factors were assessed as significant covariates, thereby influencing the mapping outcomes and
causing variation between studies.
(Continued on next page)
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Conclusions: The clinical utility of T2 and T2
* mapping to distinguish affected myocardium in patients with
cardiomyopathies or heart transplantation from healthy myocardium seemed to be confirmed based on this meta-
analysis. Nevertheless, variation of mapping values between studies complicates comparison with external values
and therefore require local healthy reference values to clinically interpret quantitative values. Furthermore, disease
differentiation seems limited, since changes in T2 and T2
* values of most cardiomyopathies are similar.
Keywords: Cardiovascular magnetic resonance imaging, Quantitative values, Cardiomyopathy, Tissue
characterization, Myocardium, Edema, Iron, Meta-analysis
Background
Ventricular dysfunction in ischemic cardiomyopathies is
triggered by impaired coronary blood supply to the myo-
cardium [1]. In non-ischemic cardiomyopathy (NICM)
many factors contribute to heart failure (HF) including
hypertrophic cardiomyopathy (HCM), dilated cardiomy-
opathy (DCM) and restrictive cardiomyopathy [2, 3].
The prevalence of HF has been rising since the year
2000 and is shown to be related to the current lifestyle
in Western Society [4, 5], with increasing populations
with high cardiovascular risk (obesity, hypertension and
type 2 diabetes mellitus (T2DM)) [6].
Early diagnosis of cardiomyopathy is important to ini-
tiate appropriate treatment [7, 8]. Physical examination
and medical history are used to assess the probability of
HF, however these assessments are non-specific in early
diagnosis and therefore require additional tests [8, 9].
Electrocardiography (ECG) is also used in the first as-
sessment of HF, and although an abnormal ECG in-
creases the probability of HF, it has low specificity and
provides little information to distinguish between cardiac
diseases [8]. Transthoracic echocardiography was sug-
gested as primary imaging test in the diagnostic pathway
of HF because of its wide availability and low costs, and
its cardiac function assessment enables fast decision
making [8, 10], it however has limitations in distinguish-
ing between underlying diseases [11]. Cardiovascular
magnetic resonance (CMR) is the golden standard to de-
tect cardiac remodelling by assessing the global cardiac
function, it allows for regional function assessment with
strain analysis and furthermore enables the assessment
of myocardial fibrosis with late gadolinium enhancement
(LGE) [8, 12–14], whereas computed tomography is rec-
ommended to either exclude or to diagnose coronary ar-
tery disease [8]. Nevertheless, early myocardial structural
changes are often qualitatively indistinguishable, and dif-
ficult to differentiate from overlapping findings in pa-
tients with high cardiovascular risk such as obesity,
hypertension and T2DM [15–18]. Consequently, misin-
terpretation of cardiac remodeling in these high cardio-
vascular risk groups may result in incorrect diagnosis
and mistreatment. The changes occurring in
cardiomyopathies, however, may affect myocardial tissue
properties, which can be measured quantitatively by T1,
T2 and T2
* mapping as part of the CMR exam [19]. In
line with this, the European Society of Cardiology re-
cently described a shifting standards from the assess-
ment of LGE towards the use of T1 and T2 mapping in
their latest position statement [20]. The clinical utility of
T1 mapping has already been acknowledged and in-
cluded in some guidelines [8, 13, 21, 22]. In addition,
other guidelines also advocate to include T2 and T2
*
mapping instead of T2-weighted imaging [20, 22–24].
The Society for Cardiovascular Magnetic Resonance
(SCMR) released clinical recommendations about para-
metric imaging in CMR [22]. T2 mapping values vary
due to different water concentrations in the myocardium
and therefore T2 mapping could be useful in infiltrative
cardiomyopathies, such as iron overload and Anderson-
Fabry disease, and in myocardial injury diseases featuring
edema, necrosis, and hemorrhage formation [22, 25, 26].
Furthermore, T2 could contribute in the diagnosis of
heart transplant rejections as edema correlates with
acute heart transplant rejection [22, 27]. In addition to
T2, T2
* mapping values mainly depend on magnetic field
inhomogeneities and are therefore clinically useful in
iron related diseases, and also enable assessment of
hemorrhage formation [22, 28, 29].
Reference values of T2 and T2
* mapping in healthy
subjects have been investigated in multiple studies
[30–33]. The heterogeneity of the data caused by dif-
ferent field strengths, imaging techniques and settings
underlines the need for local reference values [22,
33]. The objective of this study was to perform a
meta-analysis to determine the weighted mean of
myocardial T2 and T2
* mapping values in the HF-
related cardiomyopathies and heart transplantations,
and standardized mean differences (SMD) with
healthy controls. Knowledge of these ranges can help
determine the clinically applicability of quantitative
techniques. Furthermore, we aim to investigate the
presumed heterogeneity of studies leading to variation
in mapping outcomes, to emphasize the importance
of mapping standardization.
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Materials and methods
Search strategy
The study was performed according to the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement [34] and the Cochrane
Handbook for Systematic Review [35]. Three independ-
ent investigators (GS, MvdB and LH) systematically
searched for eligible studies published between January
2011 and September 2019 in PubMed/MEDLINE and
Embase applying CMR T2 or T2
* mapping in humans.
The search contained terms related to T2 or T2
* map-
ping and cardiac diseases (full search terms are listed in
Supplementary Data 1).
In this meta-analysis we accepted published results
from randomized control trials, cohort studies and ob-
servational studies in peer-reviewed journals if they in-
cluded adults aged 18 years and older with NICM or
ischemic cardiomyopathy, heart transplant patients or
adults with increased cardiovascular risk, and reported
CMR derived T2 and/or T2
* mapping values acquired at
1.5 T or 3 T. Studies were excluded if the article was not
available in English or in full text.
Study selection
Titles and abstracts proposed by the databases were
assessed for eligibility by one author and checked by a
second author (GS, MvdB and LH). After consensus be-
tween these investigators, the full-text reports of these
eligible studies were independently assessed by two in-
vestigators for final inclusion. The study quality was sys-
tematically evaluated with the Newcastle-Ottawa quality
assessment scale (NOS) [36]. This scale evaluated the
study quality on three domains: selection and definition
of included populations (0–4 points); comparability of
the controls (0–2 points); and ascertainment of the out-
come (0–3 points).
Data collection
Data were extracted from the included studies by one
author and checked by a second author (GS, MvdB and
LH). Relevant data regarding patient characteristics, such
as; study population, age, gender, body mass index, T2
and T2
* values, as well as CMR imaging acquisition re-
lated information, such as; field strength, vendor, se-
quence and sequence parameters were extracted. Data
were reported as mean ± standard deviation (SD) and
data reported as median with interquartile or full range
were converted using the methodology of Hozo et al.
[37]. Healthy control data were extracted if available.
Data analysis
The included data were divided into two groups of re-
ported T2 and T2
* values per disease and combined into
a random effects model to determine the SMD and the
95% confidence interval (CI). The heterogeneity of the
included studies was defined with I2 being significant if
I2 ≥ 50% (P < 0.05) by using a χ2 test. This heterogeneity
was further tested by a meta-regression, sensitivity and
bias analysis. Available covariates were tested for their
association with the myocardial T2 and T2
* values using
a backwards elimination model and remaining signifi-
cant covariates (P < 0.05) were included into a mixed ef-
fect model of the data. Publication bias was assessed by
inspection of the funnel plots with the Egger regression
asymmetry test and a sensitivity analysis was performed
by omitting each study sequentially and recalculating the
model. A meta-analysis was performed in each popula-
tion with at least 10 published studies, as stated by the
PRISMA guideline [34]. Review Manager (RevMan) v.
5.3 (Cochrane Collaboration, Copenhagen, Denmark)
was used to determine the random effect models and
the package “metaphor” in R v. 3.4.1 (R Foundation for
Statistical Computing, Vienna, Austria) was used for the
mixed effect models, bias and sensitivity analysis.
Results
Literature search
The search in PubMed and Embase revealed respect-
ively 555 and 545 articles, and one article was manu-
ally added [38]. After removal of the duplicates, 704
articles remained for evaluation of title and abstract
which resulted in 154 articles included for the final
meta-analysis (Table 1). In the final exclusion step
based on full text assessment, we excluded studies
which presumably included (mostly) the same patient
population as other included studies based on authors
and method; the study with the least inclusions was
excluded. The PRISMA flow diagram with rationale
for exclusion is provided in Fig. 1. The number of
studies per population was described as total studies
(number of studies reporting T2 data & number of
studies reporting T2
* data): A total of 31 (22 T2 & 13
T2
*) studies were included in the myocardial infarction
(MI) population [26, 39–68], 11 (11 T2 & 0 T2
*) in
heart transplantation [27, 69–78], 70 (5 T2 & 70 T2
*) in
iron overload [79–148], 2 (2 T2 & 0 T2
*) in sarcoidosis
[149, 150], 4 (4 T2 & 0 T2
*) in systemic lupus erythe-
matosus (SLE) [151–154], 2 (2 T2 & 0 T2
*) in amyloid-
osis [155, 156], 2 (2 T2 & 0 T2
*) in Anderson-Fabry
disease [157, 158], 4 (2 T2 & 2 T2
*) in HCM [159–162],
9 (7 T2 & 2 T2
*) in DCM [160, 163–170], 19 (19 T2 & 0
T2
*) in myocarditis [25, 38, 171–187] and 1 (0 T2 & 1
T2
*) in hypertension [188] (Table 1). The absolute T2
and T2
* values are dependent on field strength [189,
190], therefore the average mapping values were noted
separately for 1.5 T and 3 T, and it was also used as co-
variate in the meta-regression analysis. T2 and T2
*
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mapping obtained in control subjects were recorded as
values from healthy subjects, unless the control popu-
lation was explicitly defined otherwise in the “popula-
tion” column of Table 1.
Study quality
None of the included studies received the maximum
NOS quality score (Table 1). All studies without healthy
controls automatically received limited scores in the
matching and selection section. Only 57 of the 154 in-
cluded studies reported control values of healthy sub-
jects. The case definition of patients and the
ascertainment of mapping values were adequate in all
studies.
Myocardial infarction
The weighted mean T2
* values at 1.5 T in myocardial in-
farction (MI) patients was 28.5 ± 6.8 ms and 34.7 ± 3.7ms
in controls [39–49] (Table 1, Fig. 2). At 3 T, these were
22.0 ± 3.7ms in MI patients and 29.6 ± 2.7ms in controls
[50, 51] (Table 1, Fig. 3). The meta-analysis confirmed sig-
nificantly lower T2
* values in MI patients (SMD= − 1.99,
95% Cl [− 2.70, − 1.27], P < 0.01, I2 = 98%, Fig. 4). Most
studies performed CMR in ST-elevation myocardial in-
farction (STEMI) patients post percutaneous coronary
intervention (PCI) in the acute phase [39–44, 46–51].
Some studies performed follow-up in these patient groups
[42–44, 47, 49, 50] and Mohammadzadeh et al. [45] was
the only study including non-STEMI (NSTEMI) patients.
Most studies reported T2
* values of multiple regions-of-
interest (ROI) in the myocardium (Table 1). Although
none of the tested covariates was significant, the difference
in T2
* values seemed larger in the infarct cores compared
to the infarct zone as a whole. Significant funnel asym-
metry was found for the random effects model suggesting
eight missing studies with negative results (P < 0.01),
while the mixed effects model did not show funnel asym-
metry (P = 0.60).
The heterogeneity was not corrected with the existing
covariates and therefore a second analysis was per-
formed where the reported T2
* values were divided in in-
farct zone or infarct core groups. The infarct zone,
which is determined by LGE, is the affected myocardium
characterized by edema excluding the hypo-intense core,
Fig. 1 Overview of the study review process according to the PRISMA flow diagram
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which is the center in the infarct zone with T2
* values <
20ms identifying the presence of hemorrhage [40, 50].
Although during myocardial infarction no haemorrhagic
core is present, the patients were referred for CMR after
PCI in most studies. The process of reperfusion after
PCI frequently leads to simultaneous microvascular ob-
struction and intramyocardial haemorrhage within the
infarct zone [41, 191].
Eight studies [39–41, 43–45, 48, 50] explicitly reported
infarct zone values. The weighted mean T2
* value at 1.5
T of the infarct zones was 32.3 ± 5.4 ms and at 3 T this
was 22.4 ± 2.8 ms (Fig. 1, Supplementary Data 2). These
T2
* values also resulted in significantly lower values
compared to controls (SMD = − 1.21, 95% Cl [− 1.83, −
0.59], P < 0.01, I2 = 95%), and with a significant hetero-
geneity. Furthermore, infarct core values were explicitly
reported in five studies [40, 41, 43, 46, 51]. The weighted
mean T2
* value at 1.5 T of infarct cores was 16.1 ± 4.2
ms and at 3 T this was 16.1 ± 7.6 ms (Fig. 1, Supplemen-
tary Data 2). These infarct core values showed a larger
SMD (SMD = − 4.00, 95% Cl [− 5.67, − 2.32], P < 0.01,
I2 = 98%), while the heterogeneity remained significant.
Multiple studies reported the remote myocardium as
control which had a weighted mean T2
* value at 1.5 T of
34.0 ± 4.9 ms and 30.5 ± 1.0 ms at 3 T (Fig. 1, Supple-
mentary Data 2).
The weighted mean T2 values at 1.5 T in MI patients
was 58.5 ± 5.8 ms and 49.3 ± 2.6 ms in controls [26, 40,
41, 43, 49, 52–63] (Table 1, Fig. 5). At 3 T, these were
60.3 ± 9.7 ms in MI patients and 44.0 ± 3.8 ms in controls
[51, 64–68] (Table 1, Fig. 6). Most studies restricted
their inclusion to STEMI patients [40, 41, 43, 49, 51,
54–60, 63–65, 68], however some studies included spe-
cifically NSTEMI patients [52, 62, 67] and others in-
cluded both STEMI and NSTEMI patients [26, 53, 61,
66]. Besides two studies [52, 62], patients in all studies
underwent CMR post-PCI in the acute phase and a few
studies also included follow-up data [40, 42, 43, 49, 53,
64]. T2 values of different ROIs in the myocardium were
reported (Table 1), nevertheless all studies showed
higher T2 values in all ROIs of MI patients except for
studies reporting values of the hemorrhagic core [40,
41]. The meta-analysis confirmed significantly higher T2
values in MI patients (SMD = 2.17, 95% CI [1.79, 2.54],
Fig. 2 Weighted mean T2
* values and weighted standard deviations
(SD) of all included papers reporting T2
* values of both patients
(black squares) and controls (grey squares) measured at 1.5 T. The
number of included patient (p) and control (c) measurements for
each population is reported above the graph. MI myocardial
infarction, IO iron overload, HCM hypertrophic cardiomyopathy,
DCM dilated cardiomyopathy, HTN hypertension
Fig. 3 Weighted mean T2
* values and weighted standard deviations
(SD) of all included papers reporting T2
* values of both patients
(black squares) and controls (grey squares) measured at 3 T. The
number of included patient (p) and control (c) measurements for
each population is reported above the graph. MI myocardial
infarction, IO iron overload, HCM hypertrophic cardiomyopathy,
DCM dilated cardiomyopathy, HTN hypertension
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P < 0.01, I2 = 96%, Fig. 7). The age and percentage of
men in the control group, the time between intervention
and the CMR, the field strength, the type of control (re-
mote myocardium versus healthy controls), the type of
CMR acquisition sequence, the ROI location and the left
ventricular ejection fraction (LVEF) in patients were sig-
nificant covariates. There were no other significant re-
sidual factors remaining that accounted for the high
remaining heterogeneity (I2 = 78%), though there are
probably other covariates which were not tested due to
insufficient data. Publication bias was detected with five
possibly missing studies, however no significant asym-
metry was found for either the random effects model
(P = 0.10) or the mixed effects model (P = 0.55).
The ROI location was one of the covariates and there-
fore an additional analysis was performed where the re-
ported T2 values were divided in infarct zone and infarct
core groups. Infarct zone T2 values were reported in 18
studies [26, 40, 43, 51, 53, 54, 56–58, 60–68]. The
weighted mean T2 value at 1.5 T of infarct zones was
63.7 ± 6.4 ms and at 3 T this was 63.5 ± 10.5 ms (Fig. 2,
Supplementary Data 2). The difference between patients
and controls was larger when considering only the in-
farct zone values (SMD = 2.63, 95% Cl [2.25, 3.01],
P < 0.01, I2 = 93%). The meta-analysis showed older pa-
tients, a short period between intervention and CMR,
lower LVEF in patients and performing CMR on 1.5 T
to increase the difference with controls. The used CMR
acquisition sequence was also found as significant covar-
iate, nevertheless none of the specified sequences pro-
vided clearly larger differences. There were no other
significant residual factors remaining that accounted for
the heterogeneity (I2 = 80%). Again, publication bias was
found with two missing studies, however no significant
asymmetry was found for either the random effects
model (P = 0.76) or the mixed effects model (P = 0.58).
Core T2 values were reported in five studies [40, 41, 43,
56, 60]. The weighted mean T2 value at 1.5 T of infarct
cores was 51.9 ± 4.6 ms and at 3 T no values were re-
ported (Fig. 2, Supplementary Data 2). Including only
the T2 values of the infarct cores resulted in a smaller
difference between patients and controls (SMD = 0.83,
Fig. 4 Standardized mean differences between T2
* of myocardial infarction (MI) patients and healthy controls with associated random effects
weight factors. CI confidence interval, IV inverse variance
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95% Cl [0.37, 2.44], P < 0.01, I2 = 91%). The weighted
mean T2 value at 1.5 T of remote myocardium was
49.2 ± 2.5 ms and at 3 T this was 45.0 ± 3.0 ms (Fig. 2,
Supplementary Data 2).
Heart transplant
The weighted mean T2 values at 1.5 T in heart trans-
plant patients was 54.6 ± 5.2 ms and 49.2 ± 2.5 ms in
controls [27, 69–78] (Table 1, Fig. 5). All studies showed
higher T2 values in patients compared to controls, only
for all subgroups including patients with positive rejec-
tion biopsy these values were significantly higher. This
meta-analysis confirmed significantly higher T2 values in
the myocardium of heart transplant patients (SMD =
1.05, 95% CI [0.69, 1.41], P < 0.01, I2 = 65%, Fig. 8). An
exploratory meta-regression analysis indicated that the
rejection status, the LVEF and patient age caused the
heterogeneity without remaining significant residual fac-
tors (I2 = 1%). Transplant rejection, lower LVEF and
older patients resulted in larger differences between pa-
tients and controls.
The cardiac transplant rejection was a significant co-
variate and therefore the population was divided be-
tween positive and negative rejection biopsies.
The weighted mean T2 values in patients with a positive
biopsy [27, 69, 71, 73–75] was 56.4 ± 3.3 ms and 52.5 ±
3.9 ms in patients with a negative biopsy [27, 69, 71–76]
(Fig. 2, Supplementary Data 2). None of the studies to




The weighted mean T2
* values at 1.5 T in iron overload
patients was 27.2 ± 13.7 ms and 36.1 ± 6.3 ms in controls
[79–147] (Table 1, Fig. 2). At 3 T, these were 21.8 ± 7.8
ms in iron overload patients and 22.4 ± 3.8 ms in con-
trols [81, 88, 127, 148] (Table 1, Fig. 3). The meta-
analysis confirmed significantly lower T2
* values in iron
overload patients (SMD = − 2.39, 95% CI [− 3.28, − 1.49],
P < 0.01, I2 = 98%, Fig. 9). The patient populations con-
tained iron overload patients with both cardiac involve-
ment (T2
* < 20ms) and without cardiac involvement
(T2
* ≥ 20ms). Each study that included both iron over-
load patients and controls showed significantly lower T2
*
values in patients [85, 93, 95, 96, 104, 107, 113, 114, 118,
124, 128, 132, 133, 136, 139], except for two studies that
showed non-significant lower T2
* values [81, 88] and
one study that showed non-significantly higher T2
*
values in patients compared to controls [79]. The type of
control was found as a covariate which meant using
non-cardiac involved iron overload subjects as controls
caused larger differences with patients than using
healthy controls. The type of patients was also found as
covariate; using a population with proven cardiac in-
volvement caused larger differences with controls than
using a mix of non-cardiac and cardiac involved iron
Fig. 5 Weighted mean T2 values and weighted standard deviations (SD) of all included papers reporting T2 values of both patients (black
squares) and controls (grey squares) measured at 1.5 T. The number of included patient (p) and control (c) measurements for each population is
reported above the graph. MI myocardial infarction, Trans heart transplant, IO iron overload, SA sarcoidosis, SLE systemic lupus erythematosus, AM
amyloidosis, HCM hypertrophic cardiomyopathy, DCM dilated cardiomyopathy, MC myocarditis
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overload patients. Furthermore, the number of echoes
used in the T2
* sequence was determined as a covariate.
These covariates, however, only partly accounted for the
heterogeneity in the mixed effects model (I2 = 80%),
while other tested regressors (age of patient and control
population, percentage of men in patient and control
population, CMR vendor, field strength and the serum
ferritin concentration in patients) had no significant in-
fluence. Based on the high remaining heterogeneity there
should be other covariates which were not tested due to
insufficient data. Significant funnel asymmetry (P < 0.01)
was only found for the random effects model suggesting
five missing studies with populations showing higher T2
*
values compared to healthy subjects.
The type of iron overload patient was one of the
covariates and therefore an additional analysis was
performed on T2
* values from cardiac involved iron
overload patients (T2
* < 20 ms) [93, 95, 96, 104, 113,
114, 123, 124, 128, 132, 136, 139, 143, 145]. The
weighted mean T2
* value at 1.5 T in cardiac involved
iron overload patients was 11.8 ± 3.7 ms and at 3 T no
T2
* values were reported (Fig. 1, Supplementary Data
2). This analysis also showed significantly lower T2
*
values for cardiac involved iron overload patients
compared to controls (SMD = − 3.59, 95% CI [− 4.69,
− 2.48], P < 0.01, I2 = 97%) and this difference was
also larger than controls compared to the overall iron
overload population.
The weighted mean T2 values at 1.5 T in iron overload
patients was 56.0 ± 13.6 ms and 58.3 ± 3.2 ms in controls
[81, 82, 101] (Table 1, Fig. 5). At 3 T, these were 53.2 ±
6.2 ms in iron overload patients and 52.0 ± 5.5 ms in
controls [81, 93] (Table 1, Fig. 6). Kritsaineeboon et al.
[81] reported no significant changes in T2 values for iron
overload patients at both 1.5 T and 3 T, while Camargo
et al. [93] reported lower T2 values in iron overload pa-
tients at 1.5 T. The random effects models of all studies
combined resulted in no significantly lower T2 values for
iron overload patients compared to controls (SMD = −
0.54, 95% Cl [− 1.56, 0.48], P = 0.30, I2 = 86%, Fig. 10).
Sarcoidosis
The weighted mean T2 values at 1.5 T in sarcoidosis pa-
tients was 52.3 ± 3.8 ms and 49.0 ± 1.6 ms in controls
[149] (Table 1, Fig. 5). At 3 T, these were 54.0 ± 12.2 ms
in sarcoidosis patients and 45.0 ± 10.8 ms in controls
[150] (Table 1, Fig. 6). This suggested higher T2 values
in sarcoidosis patients (SMD = 0.87, 95% CI [0.55, 1.20],
P < 0.01, I2 = 0%, Fig. 11). Insufficient studies were avail-
able for further analysis regarding covariates and publi-




The weighted mean T2 values at 1.5 T in systemic lupus
erythematosus (SLE) patients was 55.7 ± 4.9 ms and
Fig. 6 Weighted mean T2 values and weighted standard deviations (SD) of all included papers reporting T2 values of both patients (black
squares) and controls (grey squares) measured at 3 T. The number of included patient (p) and control (c) measurements for each population is
reported above the graph. MI myocardial infarction, Trans heart transplant, IO iron overload, SA sarcoidosis, SLE systemic lupus erythematosus, AM
amyloidosis, HCM hypertrophic cardiomyopathy, DCM dilated cardiomyopathy, MC myocarditis
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50.6 ± 3.3 ms in controls [151, 152] (Table 1, Fig. 5). At
3 T, these were 57.3 ± 8.6 ms in SLE patients and 44.4 ±
4.0 ms in controls [153, 154] (Table 1, Fig. 6). This sug-
gested higher T2 values in SLE patients (SMD = 1.39,
95% CI [0.34, 2.44], P < 0.01, I2 = 93%, Fig. 12). Insuffi-
cient studies were available for further analysis regarding




The weighted mean T2 values at 1.5 T in amyloidosis pa-
tients was 55.3 ± 4.2 ms and 50.2 ± 2.7 ms in controls
[155, 156] (Table 1, Fig. 5). All included studies reported
higher T2 values in amyloidosis patients (SMD = 1.62,
95% CI [1.19, 2.06], P < 0.01, I2 = 76%, Fig. 13). Al-
though insufficient studies were available for further
analysis regarding covariates and publication bias, both
included studies reported higher T2 values in amyloid
light-chain amyloidosis than in transthyretin amyloid-
osis. Furthermore, there were no studies performed with




The weighted mean T2 value at 1.5 T in Anderson-Fabry
disease patients was 57.7 ± 3.0 ms [157, 158] (Table 1,
Fig. 7 Standardized mean differences between T2 of myocardial infarction (MI) patients and healthy controls with associated random effects
weight factors. CI confidence interval, IV inverse variance
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Fig. 5). One study reported T2 values in controls of
47.5 ± 2.4 ms [158], suggesting a trend to higher T2
values in Anderson-Fabry disease patients (SMD = 0.52,
95% Cl [− 0.23, 1.28], P = 0.17, I2 = 71%, Fig. 14). The
higher T2 values in Anderson-Fabry disease patients
were caused by the reported T2 values in Anderson-
Fabry disease patients with left ventricular hypertrophy
(LVH) (50.4 ± 3.8 ms), while patients without LVH
showed similar T2 values (47.8 ± 1.7 ms) to controls. In-
sufficient studies were available for further analysis re-
garding covariates and publication bias. Furthermore,
there were no studies performed with T2 values on 3 T
and there were no data that described T2
* values.
Hypertrophic cardiomyopathy
The weighted mean T2
* values at 1.5 T in HCM patients
from one study was 26.4 ± 4.4 ms and 31.3 ± 4.3 ms in
controls [159] (Table 1, Fig. 2). At 3 T, these were
22.3 ± 4.1 ms in HCM patients and 21.0 ± 6.4 ms in con-
trols [160] (Table 1, Fig. 3). The study performed at 1.5
T reported values in subgroups based on the presence of
fibrosis (with or without LGE) and in both subgroups
the T2
* value was lower compared to controls, which
was only significant in the group with LGE presence
[159]. In the study performed at 3 T there, however, was
no significant difference in T2
* values between HCM pa-
tients with or without LGE presence. As result, the ana-
lysis showed a no significant difference between HCM
patients and controls (SMD = − 0.61, 95% CI [− 1.58,
0.36], P = 0.22, I2 = 87%, Fig. 15). Insufficient studies
were available for further analysis regarding covariates
and publication bias.
The weighted mean T2 value at 1.5 T in HCM pa-
tients was 56.3 ± 4.0 ms [161, 162] (Table 1, Fig. 5).
One study reported T2 values in controls of 48.1 ±
3.2 ms suggesting significantly higher T2 values in
HCM patients [161] (SMD = 1.95, 95% Cl [0.93, 2.97],
I2 = N/A, P < 0.01, Fig. 16). In that same study [161]
the T2 values were measured in the patient myocar-
dium with visually high T2, which was present in 38%
of the patients. For the patients without LGE in that
study the myocardial T2 value of 48.8 ± 2.4 ms was
not significantly different from controls. Furthermore,
there were no studies performed with T2 values ac-
quired at 3 T and insufficient studies were available
for further analysis regarding covariates and publica-
tion bias.
Dilated cardiomyopathy
The weighted mean T2
* value at 3 T in DCM patients
was 22.7 ± 3.6 ms [160, 163] and only one of those
studies reported T2
* values in controls of 21.0 ± 6.4
ms [160] (Table 1, Fig. 3). The random effects model
was therefore only based on that study, and since that
study reported T2
* values of 18.7 ± 3.1 ms in DCM pa-
tients there was no significant change in T2
* values
(SMD = − 0.54, 95% Cl [− 1.09, 0.01], I2 = N/A, P =
Fig. 8 Standardized mean differences between T2 of heart transplant patients and healthy controls with associated random effects weight factors.
CI confidence interval, IV inverse variance
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Fig. 9 Standardized mean differences between T2
* of iron overload patients and healthy controls with associated random effects weight factors.
CI confidence interval, IV inverse variance
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0.06, Fig. 17). In both studies, patients had chronic
established DCM and without myocarditis or other
cardiomyopathies [160, 163]. Furthermore, there were
no studies performed with T2
* values acquired at 1.5
T and there were also insufficient studies available for
further analysis regarding covariates and publication
bias.
The weighted mean T2 values at 1.5 T in DCM pa-
tients was 62.9 ± 5.7 ms and 55.4 ± 3.5 ms in controls
[164–169] (Table 1, Fig. 5). At 3 T, these were 47.0 ± 5.0
ms in DCM patients and 45.0 ± 3.0 ms in controls [170]
(Table 1, Fig. 6). All studies reported significantly higher
T2 values in DCM patients compared to controls, except
for the single study performed at 3 T [170]. The similar
T2 values of patients and controls in this study might be
related to their ROI placement, since they explicitly ex-
cluded positive LGE segments from the ROI, while all
other studies used the entire myocardium without ex-
cluding positive LGE segments [164–169]. Nevertheless,
the T2 values of positive and negative LGE segments
were similar in all studies that reported T2 values of
both segments [166–168]. The overall meta-analysis
confirmed the significantly higher T2 values in DCM pa-
tients (SMD = 1.90, 95% CI [1.07, 2.72], P < 0.01, I2 =
89%, Fig. 18) and an exploratory meta-regression ana-
lysis indicated the MR vendor and the age difference be-
tween DCM patients and controls as possible covariates.
The use of a Philips Healthcare CMR scanner and a big-
ger age difference between control and patient groups
resulted in a larger SMD between DCM patients and
controls.
Myocarditis
The weighted mean T2 values at 1.5 T in myocarditis pa-
tients was 61.9 ± 11.5ms and 54.4 ± 5.9ms in controls [25,
38, 171–185] (Table 1, Fig. 5). At 3 T, these were 63.8 ±
8.0ms in myocarditis patients and 53.3 ± 3.3ms in controls
[186, 187] (Table 1, Fig. 6). The meta-analysis confirmed
significantly higher T2 values in myocarditis patients
(SMD= 1.33, 95% CI [1.00, 1.67], P < 0.01, I2 = 84%,
Fig. 19). Multiple significant covariates were identified in-
cluding; the difference in LVEF between patients and con-
trols, the difference in percentage men between patients
and controls, the time between symptoms and CMR, the
number of echoes used in the CMR acquisition sequence,
the CMR vendor and the slice thickness. These covariates
together corrected for the total heterogeneity (I2 = 0%) and
resulted in a larger SMD between myocarditis patients and
controls when the same percentages of men was used in
both groups, a significantly decreased LVEF was seen in
patients, six echoes were acquired for the mapping, a Sie-
mens Healthineers CMR vendor was used, a bigger slice
thickness was used, and when the patients were scanned in
the acute phase of myocarditis. Significant asymmetry was
not found for either the random effects model (P = 0.12)
or the mixed effects model (P = 0.10).
The time between symptom onset and CMR was
found as significant covariate and therefore the popula-
tion was divided between T2 values from patients in the
acute phase and non-acute phase [192]. Acute myocardi-
tis in patients was diagnosed using the European Society
of Cardiology guideline [193] and these patients were re-
ferred for CMR shortly after symptom onset in the acute
Fig. 10 Standardized mean differences between T2 of iron overload patients and healthy controls with associated random effects weight factors.
CI confidence interval, IV inverse variance
Fig. 11 Standardized mean differences between T2 of sarcoidosis patients and healthy controls with associated random effects weight factors. CI
confidence interval, IV inverse variance
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phase (< 14 days). Myocarditis patients in the non-acute
phase either had chronic symptom duration (> 14 days)
or underwent CMR follow-up. The weighted T2 value of
myocarditis patients in the acute phase at 1.5 T was
63.5 ± 15.0 ms and at 3 T this was 63.8 ± 8.0 ms [25, 38,
167, 172–179, 181, 183–187] (Fig. 2, Supplementary
Data 2). The weighted T2 value of myocarditis patients
in the non-acute phase at 1.5 T was 58.3 ± 4.3 ms [173,
174, 179, 185] and at 3 T no T2 values were reported
(Fig. 2, Supplementary Data 2). Furthermore, there were
no studies that described T2
* values for myocarditis.
Hypertension
One study reported T2
* values at 1.5 T in hypertension
patients of 26.3 ± 3.7 ms and 30.8 ± 2.7 ms in controls
[188] (Table 1, Fig. 2). This suggested lower T2
* values
in hypertension patients, nevertheless this was not sig-
nificant (SMD = − 1.46, 95% CI [− 3.21, 0.29], P = 0.10,
I2 = 92%, Fig. 20). This study classified the included
hypertension population in either presence of LVH or
no presence of LVH, and showed in both subgroups
lower T2
* values, however in hypertension patients with
LVH the T2
* values were lowest. Furthermore, insuffi-
cient studies were available for further analysis regarding
covariates and publication bias, and there were no stud-
ies that described T2
* values acquired at 3 T or T2 re-
sults. Also, no published data was found on T2 or T2
*
for the cardiovascular risk populations obesity and
diabetes.
Discussion
Quantitative analysis of factors that modulate myocardial
T2 and T2
*, such as edema, lipids and paramagnetic
iron-containing depositions, can potentially provide add-
itional diagnostic information to distinguish between
myocardial diseases and healthy myocardium. This
meta-analysis confirmed that T2 mapping can help dif-
ferentiate between healthy subjects and patients affected
by MI, DCM, myocarditis or heart transplantation, since
T2 values were higher in these populations [22]. Al-
though T2 mapping has been expected to be sensitive to
iron as well [22], no significantly lower T2 values were
found between iron overload related diseases and
healthy myocardium (P = 0.30). On sarcoidosis, SLE,
amyloidosis, sarcoidosis, Anderson-Fabry disease and
HCM insufficient studies were reported for further ana-
lysis, nevertheless the available data suggested T2 values
to be higher within these diseases, with an exception for
Anderson-Fabry disease patients without LVH. Further-
more, this meta-analysis confirmed that T2
* mapping
can differentiate between healthy myocardium and myo-
cardium affected in MI and iron overload, since T2
*
values were lower in both of these populations [22]. For
HCM, DCM and hypertension patients, the limited
Fig. 13 Standardized mean differences between T2 of amyloidosis (AM) patients and healthy controls with associated random effects weight
factors. CI confidence interval, IV inverse variance
Fig. 12 Standardized mean differences between T2 of systemic lupus erythematosus patients and healthy controls with associated random
effects weight factors. CI confidence interval, IV inverse variance
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available T2
* mapping studies also gave some indication
of lower T2
* values compared to controls, however this
was overall not significant. For all included cardiac dis-
eases in this meta-analysis the T2 values were higher,
with iron overload patients as an exception showing
lower T2 values, and T2
* values were lower. These simi-
larities in T2 and T2
* values between cardiac diseases
prevent further differentiation in disease type, as op-
posed to differentiation from the healthy.
Reported T2 and T2
* values in healthy subjects showed
large variation between studies, which could partly be due
to the lack of acquisition standardization. In the standard-
ized CMR imaging guideline and protocol published in
2013 [194], T2
* mapping was only described as a clinical
applicable technique to assess cardiac iron deposition and
T2 mapping was defined as a research-domain technique
[194, 195]. T2 mapping sequences were stated as optional
since there was no standardization yet [194], which led to
different acquisition approaches and therefore potentially
acquisition related variation in T2 values. In 2017, clinical
recommendations were released regarding parametric im-
aging of both T2 and T2
* mapping and defined standard-
ized data acquisition and analysis [22]. They stated that
local healthy T2 and T2
* values should be determined in
order to clinically use these quantitative techniques, which
is now confirmed by this meta-analysis considering the
wide variation of healthy T2 and T2
* values (Figs. 2, 3, 5
and 6). The use of normal scan results of clinically re-
ferred patients could be used to determine reference
values, however this is not recommended due to referral
bias. Age- and gender-matching of the control group is
necessary [22], since both are known to influence T2 and
T2
* values [30]. Furthermore, the clinical recommenda-
tions also stated specific imaging protocols, technical re-
quirements of sequences and image planning for T2 and
T2
* mapping, which should reduce variability in image ac-
quisition from then onward [22]. This meta-analysis in-
cludes multiple studies that were published prior to this
guideline and showed the heterogeneity to be significantly
influenced by the sequence based covariates, which has
previously already been concluded from a direct compari-
son between sequences [196]. This analysis also showed
the variation between CMR vendors with on 1.5 T healthy
control T2 values of 54.9 ± 3.3ms at Philips (n = 13 stud-
ies) and 50.0 ± 2.5ms at Siemens (n = 22) and T2
* values
of 34.1 ± 6.5ms at Philips (n = 5), 30.8 ± 4.5 ms at Siemens
(n = 3) and 55.0 ± 13.0ms at General Eletric (GE) (n = 1),
and on 3 T healthy control T2 values of 44.7 ± 5.8ms at
Philips (n = 6) and 48.0 ± 3.0ms at Siemens (n = 5), and
T2
* values of 23.9 ± 4.7 at Philips (n = 2), 21.0 ± 4.8ms at
Siemens (n = 1) and 21.0 ± 6.4 ms at GE (n = 1). These dif-
ferences in vendor and field strength should be kept in
mind when T2 and T2
* values are used within a clinical
protocol.
In addition to the clinical guideline on T2 and T2
* ac-
quisitions [22], following the recommendations in image
analysis could reduce the non-physiological variation of
T2 and T2
* values. The clinical recommendations on
acquisition and ROI placement are described specifically
per disease [22], and this meta-analysis confirmed the dif-
ferent approaches in analysis. In general the ROI should
be placed outside positive LGE myocardium areas and
Fig. 14 Standardized mean differences between T2 of Fabry disease patients and healthy controls with associated random effects weight factors.
CI confidence interval, IV inverse variance
Fig. 15 Standardized mean differences between T2
* of hypertrophic cardiomyopathy (HCM) patients and healthy controls with associated
random effects weight factors. CI confidence interval, IV inverse variance
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include non-fibrous myocardium [22]. T2 values mea-
sured in positive LGE myocardium should therefore be
interpreted cautiously. Analysis of T2 in diffuse diseases,
such as HCM and DCM, were mostly performed based
on one or three short axis (SAx) slices using global as-
sessment [162, 164–169], as recommended [22]. In
patchy diseases, such as amyloidosis and Anderson-
Fabry disease, the recommendations state that the T2
analysis should also include a single 3 chamber or
4 chamber view acquisition additionally to basal and
mid-ventricular SAx slices [22]. Only one study actually
followed these recommendations [158], while for the
other cardiac patchy disease studies one or more recom-
mended slices were not included [155–157]. In focal dis-
eases, such as MI and myocarditis, the ROI differs
between patients because the location of the abnormality
is different, and therefore the guideline recommends
multiple SAx acquisition to cover the whole myocar-
dium and to place the ROI in visually abnormal myocar-
dium [22]. Most included studies in this meta-
analysis therefore acquired multiple SAx slices [51, 54–
56, 61, 63, 65], however some studies acquired only one
[60] or three [49] SAx slices at the level of the infarcted
area, which is more prone to missing the infarct core. In
the studies with myocarditis patients mapping acquisi-
tion was generally also performed over multiple SAx
covering the whole myocardium [38, 171–173, 175–180,
182, 183, 185], however in some studies the T2 values
were only acquired from a LGE hyperintense based ROI
[25, 174, 181, 184, 187]. Also, studies including MI, often
distinguish between the infarct region or core and use
remote myocardium as the healthy control tissue. In
these studies the ROI placement was generally based on
LGE hyperintense regions [26, 41, 49, 51, 57, 58, 60–63,
65, 67, 68], 2SD change of T2 signal intensity [40, 43, 54,
56, 59, 60] or T2
* values [41, 43, 56]. This meta-analysis
showed that ROI placement significantly influences the
T2 and T2
* outcome and the separate analysis showed
the infarct zone to have a larger T2 difference with con-
trols than the infarct core, while the infarct core showed
a larger T2
* difference with controls than the infarct
zone. Lastly, for studies including iron overload patients
most T2
* measurements were performed in the intraven-
tricular septum for reproducibility, because the lateral
wall often contains dephasing artefacts. Nevertheless,
some studies reported an average of the mid-ventricular
SAx slice [87, 115, 119, 134] or the entire myocardium
[106, 125, 127–132], which especially on 3 T [127] could
lead to some unrealistic T2
* values due to aforemen-
tioned artefacts.
In this meta-analysis including MI patients other co-
variates aside from the ROI placement had a significant
effect on T2 and T2
* mapping outcomes. These covari-
ates included the use of remote myocardium as control
values instead of healthy controls, the timing of CMR
acquisition after reperfusion, and the sequence that was
used. The first covariate that included the use of remote
myocardium as control, showed that remote myocar-
dium is physiologically different from healthy tissue and
therefore is not an appropriate control tissue [197, 198].
Followed by the second covariate for timing of the CMR
imaging after PCI, for which histologically is verified in
swine that edema and haemorrhage formation peaks in
the acute phase 2 h and 7 days post-PCI [199] . These
Fig. 17 Standardized mean differences between T2
* of dilated cardiomyopathy (DCM) patients and healthy controls with associated random
effects weight factors. CI confidence interval, IV inverse variance
Fig. 16 Standardized mean differences between T2 of hypertrophic cardiomyopathy (HCM) patients and healthy controls with associated random
effects weight factors. CI confidence interval, IV inverse variance
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peaks were also detected in the acquired T2 values in
humans at the same day and at 10 days post-PCI, com-
pared to 3 days post-PCI [43]. These results were contra-
dicted by another study [64] that reported higher T2
values at 3 days post-PCI compared to the same day or at
7 days post-PCI. The third covariate showed that the use
of a spin-echo based sequence provides larger differences
between MI patients and controls, than the gradient-
echo-spin-echo or T2-prepared balanced steady-state free
procession sequences, while the latter two are currently
recommended in the general guideline [22]. Lastly due to
the remaining high heterogeneity of the MI meta-analysis
other covariates are expected to influence the T2 and T2
*
mapping outcomes in addition to the ones identified here.
In this meta-analysis including heart transplant pa-
tients the main distinct covariate was the rejection status
of the transplanted heart. Acute cellular rejection is
characterized by infiltration of inflammatory cells ac-
companied with edema resulting in higher T2 values [22,
200], which was also reported in most included studies
Fig. 18 Standardized mean differences between T2 of dilated cardiomyopathy (DCM) patients and healthy controls with associated random
effects weight factors. CI confidence interval, IV inverse variance
Fig. 19 Standardized mean differences between T2 of myocarditis (MC) patients and healthy controls with associated random effects weight
factors. CI confidence interval, IV inverse variance
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[22, 27, 71–73, 75, 76, 200]. Nevertheless, patients with
negative biopsies also showed higher T2 values than con-
trols [69, 71, 75], suggesting that the higher T2 values in
heart transplant patients may also be related to the in-
flammatory changes from the transplantation process.
The exploratory meta-analysis, however, indicated that
positive rejection was a significant covariate to result in
larger differences of T2 values between heart transplant
patients and healthy controls [27, 72, 73, 77], and there-
fore further research is needed to investigate the clinical
applicability of T2 mapping for early detection of heart
transplant rejection.
In this meta-analysis all transfusion-dependent dis-
eases leading to iron overload were evaluated in one
group including thalassemia, sickle cell disease and anae-
mias [201]. The overall average T2
* value for iron over-
load patients was 27.2 ± 13.7 ms, which was above the
established iron overload cut-off (T2
* < 20ms) [195].
This could be due to the fact that most studies reported
T2
* values without distinguishing between cardiac or
non-cardiac iron overload involvement. Some studies
provided T2
* values of cardiac involved patients using <
20ms as a clinical cut-off [22]. Consequently, the mean
T2
* value of these cardiac involved patients was only
11.8 ± 3.7 ms, which was significantly lower than the
controls. The type of controls should ideally only include
healthy volunteers, however in some studies also non-
cardiac involved iron overload patients were used as
controls. The T2
* value from real healthy volunteers of
32.4 ± 5.6 ms [79, 81, 85, 88, 93, 107, 118, 133] was lower
than the 35.7 ± 6.4 ms from non-cardiac iron overload
patients [95, 96, 104, 113, 114, 124, 127, 132], and there-
fore the accuracy of the T2
* < 20 ms cut-off to establish
cardiac involvement could be challenged. The current
recommendation advises to perform T2
* mapping on 1.5
T, since higher field strengths show more susceptibility
artefacts [22]. Nonetheless, two studies [81, 88] were
performed at 3 T as well as 1.5 T including patients and
controls, in which ROI placement was performed at the
mid-ventricular septum to avoid susceptibility artefacts
[22]. As expected, these studies showed a larger SMD
between healthy controls and iron overload patients at 3
T compared to 1.5 T (SMD of − 0.27 and − 0.16), since
the transverse relativity of paramagnetic substrates in-
creases with field strength [202]. These last findings
show that iron overload evaluation on 3 T seems to be a
trade-off between increased risk on artefacts and a
higher iron sensitivity.
Furthermore, T2 mapping was expected to be sensitive
for iron overload [22], however this was not unequivo-
cally confirmed by this meta-analysis (SMD = − 0.54, P =
0.30). One study performed on 1.5 T and 3 T showed no
statistically significant T2 changes in iron overload pa-
tients [81], while others did show clear changes in T2
values [82, 93, 101]. In this first study only 6% of their
patients had cardiac involvement, which might explain
the lack of change in T2. The other studies showed a
high correlation between T2 and T2
* changes and signifi-
cantly lower T2 values in patients with cardiac involved
iron overload compared to healthy controls suggesting
that T2 to could indeed be sensitive to iron overload [82,
93, 101]. More research is needed to validate this
conclusion.
In Anderson-Fabry disease only patients with LVH
showed significantly higher T2 values compared to
healthy controls [158]. Previous research showed that
native T1 mapping is the most sensitive CMR par-
ameter in Anderson-Fabry disease and that
Anderson-Fabry disease patients showed lower T1
values than controls regardless of LV function and
morphology, and therefore T1 mapping is also sensi-
tive to distinguish between controls and Anderson-
Fabry disease patients without LVH [203]. One
study, which was not included within this meta-
analysis because it was published previous to our
search period, also reported higher T2 values in
Anderson-Fabry disease patients compared to both
HCM patients and healthy controls, suggesting that
T2 mapping is also a sensitive CMR marker to early
assess cardiac involvement in Anderson-Fabry dis-
ease patients without LVH [204].
The higher T2 values in DCM patients found in this
meta-analysis confirmed the immunohistologal evidence
of chronic myocardial inflammation for this disease
[205]. Studies reporting T2 values of DCM subgroups
seemed contradicting, since one study [166] showed
Fig. 20 Standardized mean differences between T2
* of hypertension (HTN) patients and healthy controls with associated random effects weight
factors. CI confidence interval, IV inverse variance
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higher T2 values in severe DCM compared to mild
DCM (P < 0.05), while another [167], though not signifi-
cant, showed lower T2 values in severe DCM compared
to mild DCM. Nevertheless, overall higher T2 values in
DCM patients was confirmed by this meta-analysis.
This meta-analysis including studies with myocarditis
patients confirmed the expected higher T2 values in the
acute phase. All studies reported significantly higher T2
values except for one study that showed non-
significantly higher T2 values in the acute phase com-
pared to healthy controls, with 65.3 ± 45.4 ms and 53.7 ±
31.0 ms, respectively, which was mainly due to the broad
SD of both groups [184]. Aside from the higher T2
values in the acute phase, a follow-up study showed that
3 and 12months after symptom onset the T2 values
returned to normal [174]. Another follow-up study con-
firmed these normal T2 values at 189 days after symptom
onset, and also showed that after 40 days the T2 values
were still significantly higher compared to healthy con-
trols, with 52.4 ± 1.0 ms and 50.4 ± 2.3 ms, respectively
[185]. These follow-up studies suggest that T2 mapping
in myocarditis is most valuable in the acute phase in
addition to the Lake Louise criteria that include hist-
ology and CMR with T1- and T2-weighted imaging.
The single study that reported T2 values from HCM
patients and controls showed significantly higher T2
values in patients [158]. Two studies compared the T2
*
values from HCM patients with healthy controls, how-
ever their results were contradicting. One study at 1.5 T
reported significantly lower T2
* values in HCM patients
compared to controls with 26.2 ± 4.6 ms and 31.3 ± 4.3
ms, respectively [159], whereas the other study at 3 T re-
ported no significant difference with 22.3 ± 4.1 ms and
21.0 ± 6.4 ms, respectively [160]. Since early treatment is
key for HCM patients, it is important to be able to dis-
tinguish LVH changes due to either HCM or to hyper-
tension. Differentiating between HCM and hypertension
related LVH using only parametric imaging is not pos-
sible, as this differentiation depends on multiple clinical
factors [13]. Nevertheless one study reported on hyper-
tension patients and showed lower T2
* values at 3 T for
both hypertension patients with LVH (23.8 ± 3.1 ms) and
without LVH (28.6 ± 4.2 ms) compared to healthy con-
trols (30.8 ± 2.7 ms) [50]. Based on these limited avail-
able studies no conclusion can be drawn on the clinical
relevance of T2 and T2
* mapping. More research could
enable to determine the clinical applicability of these
mapping techniques, while T1 mapping has already
shown to be promising in distinguishing hypertension
related LVH and HCM [21, 206]. Furthermore, as the in-
cidence of cardiomyopathies is related to obesity and
T2DM [8] it is important to determine whether these
high cardiovascular risk factors cause myocardial tissue
adaptation and if these are distinguishable with
quantitative techniques. Unfortunately, no T2 and T2
*
mapping of these risk populations is yet, and therefore
we have to rely on the values of cardiac diseases without
considering these risk factors.
Conclusion
This meta-analysis showed that T2 and T2
* values of
both patients and healthy controls demonstrate variation
between studies related to differences in population
demographics, CMR vendor, acquisition methods and
analysis approach. This variation limits comparison be-
tween centers and therefore each center requires local
T2 and T2
* reference values to distinguish affected myo-
cardium in cardiomyopathies from healthy myocardium.
To this end reference values should be obtained in, pref-
erably matched, healthy controls using the same CMR
acquisition method as in patient care. Although similar-
ities of changes in T2 and T2
* values between cardiac
diseases limits direct differentiation, this paper provides
T2 and T2
* mapping data which, together with other
CMR parameters such as T1 mapping, ECV and LGE,
can help to differentiate between cardiac disease entities.
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